Amplia Therapeutics Ltd has released a press release.
Second Complete Response in ACCENT Pancreatic Cancer Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Pathological complete response recorded in patient from ACCENT cancer trial
- Pathological Complete Response in Pancreatic Cancer Trial
- Preliminary Final Report and Annual Report YE 31 March 2025
- ACCENT Trial Achieves Superiority over Chemotherapy Alone
- Completion of Recruitment of ACCENT Trial
Later from Amplia Therapeutics
- Amplia announces A$25m Placement and Launches A$2.5m SPP
- Capital Raising Presentation
- Positive ACCENT Trial Topline Data Released
- Amplia Share Purchase Plan Raises $2.65 Million
- First patient dosed in new pancreatic cancer trial
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics